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In several species, a family of nuclear receptors, the peroxisome proliferator-activated receptors (PPARs) composed of three iso-
types, is expressed in somatic cells and germ cells of the ovary as well as the testis. Invalidation of these receptors in mice or
stimulation of these receptors in vivo or in vitro showed that each receptor has physiological roles in the gamete maturation or
the embryo development. In addition, synthetic PPARγ ligands are recently used to induce ovulation in women with polycystic
ovary disease. These results reveal the positive actions of PPAR in reproduction. On the other hand, xenobiotics molecules (in her-
bicides, plasticizers, or components of personal care products), capable of activating PPAR, may disrupt normal PPAR functions
in the ovary or the testis and have consequences on the quality of the gametes and the embryos. Despite the recent data obtained
on the biological actions of PPARs in reproduction, relatively little is known about PPARs in gametes and embryos. This review
summarizes the current knowledge on the expression and the function of PPARs as well as their partners, retinoid X receptors
(RXRs), in germ cells and preimplantation embryos. The eﬀects of natural and synthetic PPAR ligands will also be discussed from
the perspectives of reproductive toxicology and assisted reproductive technology.
Copyright © 2008 Jaou-Chen Huang. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisomes are organelles in eukaryotes that remove
toxic substances and break down fatty acid. Peroxisome
proliferator-activated receptor α (PPARα) was discovered
during the search for a compound that increases the prolifer-
ation of peroxisomes in mouse liver cells [1]. Subsequently,
two additional isotypes, PPARβ (also known as PPARδ)a n d
PPARγ, were discovered. The three PPARs are encoded by
diﬀerent genes. Variants arising from alternative splicing and
usage of diﬀerent promoters have been reported in all three
PPARs[2].Togethertheyformasubfamilywithinthesteroid
receptor superfamily. To date, PPARs have been identiﬁed in
many species, including Xenopus, sea squirt, zebraﬁsh, Aedes
aegypti(yellowfevermosquito),Anophelesgambiae(aspecies
complex which contains six vectors of malaria), mouse, rat,
hamster, and human (http://www.ensembl.org/index.html).
Since their discovery, a great deal has been learned about
PPARα,P P A R γ, and, to a less extent, PPARβ/δ. The knowl-
edge has been applied to clinical practice: synthetic PPARα
ligands (ﬁbrates) and PPARγ ligands (thiazolidinediones
TZD), respectively, are widely used to treat lipid and glu-
cose disorders. In contrast, the use of PPARs to enhance fer-
tility is constrained by our relative meager knowledge re-
garding PPARs and reproduction. PPARγ activators have re-
cently been used to induce ovulation in women with poly-
cystic ovary disease, a condition of ovulation dysfunction as-
sociated with insulin resistance. This review will focus on the
rolesofPPARsinthedevelopmentandphysiologyofgametes
and preimplantation embryos. Also included in the discus-
sion are potential impacts of natural or synthetic PPAR lig-
and on reproduction and the promising beneﬁts of synthetic
PPAR ligands in enhancing the success of assisted reproduc-
tive technology.
2. PPARs AND RXRs
PPARs,similartosteroidand thyroidhormonereceptors, are
ligand-activated nuclear transcription factors. Unlike steroid2 PPAR Research
and thyroid hormone receptors, PPARs were discovered be-
fore their functions were fully understood. Over the years,
tissue distribution and synthetic ligands, which bind to spe-
ciﬁc PPAR, helped to elucidate the biological functions of
PPARs.
PPARs form heterodimers with another nuclear recep-
tor, retinoid X receptor (RXR). This interaction occurs
in the presence and absence of PPAR ligand. The PPAR-
RXR complex recruits other cofactors before binding to
PPAR responsive element (PPRE) at the promoter regions of
PPAR-responsive genes. Besides PPARs, RXR also forms het-
erodimers with other nuclear receptors. RXR has three iso-
types: RXRα,R X R β,a n dR X R γ,a l lo fw h i c ha r ea c t i v a t e d
by 9-cis-retinoic acid (but not by all-trans retinoic acid) [3].
The 9-cis-retinoic acid was originally considered as the en-
d o g e n o u sl i g a n df o rR X R si nv i v o ;b u tr e c e n tr e p o r t s[ 4, 5]
cast considerable doubt that it is the case. Although RXRs
exist as three isotypes, they do not confer diﬀerent func-
tions to PPAR-RXR complexes. The PPAR-RXR complexes
are activated by either PPAR or RXR ligand, but simulta-
neous binding by both ligands elicits more potent activities
[6]. A unique feature of PPARβ/δ, not seen in PPARα or
PPARγ, is its ability to repress the transcriptional activities of
PPARα and PPARγ. This activity is mediated by corepressors
recruited by PPARβ/δ [7].
The DNA sequence of PPRE is typically of a direct repeat
1 (DR1) nuclear receptor in that the PPRE DNA sequence
consists of two repeats of AGGTCA separated by one nu-
cleotide (AGGTCA N AGGTCA). Detailed analyses of na-
tive PPREs show that the consensus PPRE sequence is 5 -
AACTAGGNCAAAGGTCA-3  [6].Theextended5  halfsite,
the one imperfect DR1 core, and the adenine as the spacing
nucleotide may confer additional selectivity to the binding of
PPAR-RXR complex.
3. DISTRIBUTION AND BIOLOGICAL
FUNCTIONS OF PPAR
The functions of PPARs can be extrapolated from tissue(s)
expressing the speciﬁc PPAR isotype or from thefunctions of
genes regulated by speciﬁc PPAR. PPARα is expressed most
abundantly in brown adipose tissue and liver, followed by
the kidney, heart, and skeletal muscle. PPARγ is mainly ex-
pressedinadiposetissueand,toalessextent,inthecolon,the
immune system, and the retina. Both PPARα and PPARγ re-
sponsive genes are involved in lipid homeostasis. Therefore,
it is not surprising that the main functions of PPARα and
PPARγ are in glucose and lipid homeostasis [6, 8].
On the other hand, the ubiquitous distribution of
PPARβ/δ (althoughgut,kidney,andheartexpresshigherlev-
els than other tissues) makes it diﬃcult to associate PPARβ/δ
with speciﬁc biological function [8]. The multiple functions
of PPARβ/δ are revealed by the diverse genes regulated by
PPARβ/δ, such as ILK [9], 11 ß hydroxysteroid dehydroge-
nase II [10], PTEN [9], and 14-3-3ε [11]. It is worth not-
ing that 14-3-3ε functions as a protein chaperone. There-
fore,PPARβ/δ isindirectlyassociatedwithevenmorediverse
range of functions. Indeed, PPARβ/δ has been implicated in
embryo implantation [12], intestinal adenoma [13], colon
cancer [14], skin wound healing [15], hair follicle develop-
ment [16], and cytoprotection [11].
4. PPAR LIGANDS
Natural and synthetic PPAR ligands relevant to this review
are listed below. More extensive lists are available in the liter-
ature [6, 17].
Unsaturated fatty acids are ligands to all PPARs,
with PPARα exhibiting the highest aﬃnity; saturated fatty
acids, on the other hand, are not eﬀective PPAR lig-
ands. Eicosanoids derived from arachidonic acid form a
unique group of fatty acids that bind to PPARs. They in-
clude leukotrienes, hydroxyeicosatetraenoic acids (HETEs)
(both are formed via the lipoxygenase pathway), and
prostaglandins (PGs) (formed via the cyclooxygenase path-
way). Leukotriene B4 and 8(S)-HETE are PPARα ligand; and
15-deoxy-Δ12, 14-PGJ2 (15d-PGJ2,aP G D 2 derivative) is a
PPARγ ligand.SyntheticPPARα(ﬁbrates)andPPARγ (TZD)
ligands are used to lower blood lipid and glucose, respec-
tively. Prostacyclin (PGI2)i san a t u r a lP P A R β/δ ligand, in-
deed the uterine PGI2 generated by cyclooxygenase-2 (COX-
2) mediates the implantation of embryos via PPARβ/δ [12].
Synthetic PGI2 analogs, such as iloprost and carbaprostacy-
clin, may function as PGI2 receptor agonists or PPARβ/δ lig-
ands. Although iloprost is used as a PGI2 receptor agonist to
treat pulmonary hypertension and peripheral vascular dis-
eases, no PGI2 analog has been used as a PPARβ/δ ligand
clinically. A recent report indicates that retinoic acid, in cells
with high fatty acid binding protein 5 to retinoic acid bind-
ing protein-II ratio, may function as a natural PPARβ/δ lig-
and [18]. This ﬁnding may have evolutional or developmen-
tal signiﬁcance in germ cell maturation, gamete function, or
embryo development. PGI2 and retinoic acid may provide
functional redundancy to ensure PPARβ/δ activation or they
may compliment each other to activate PPARβ/δ in a devel-
opmental stage-dependent manner based on the ratio of the
two binding proteins.
5. PPAR LIGANDS IN THE REPRODUCTIVE TRACT
Zygotes remain in the oviduct after fertilization and develop
to morula or early blastocyst stage embryos before enter-
ing into the uterus. It is generally accepted that, compared
with cultured embryos (derived from fertilized eggs in vitro
or ﬂushed from oviducts at earlier developmental stage), in
vivo embryos develop better and have less cell death because
oviducts protect the embryos and promote their develop-
ment [19]. The unique environment provided by the oviduct
includesoviduct-derivedsolublefactorsandembryo-derived
autocrine factors. Both oviducts and embryos are sources of
PPAR ligand(s).
Earlier studies show that the oviduct produces abun-
dant PGE2 and PGF2α, which regulate its motility. We
serendipitously discovered that human [20]a n dm o u s e[ 21]
oviducts produce other eicosanoids that activate PPARs.
PGI2 (a PPARβ/δ ligand) is the most abundant product,
PGD2 (whose derivative, 15d-PGJ2,i saP P A R γ ligand), and
other products derived from the lipoxygenase pathway areJaou-Chen Huang 3
also produced in substantial amounts. PGI2 synthesis by
mouseoviductsissynchronizedwithestruscycles(and,thus,
the development of preimplantation embryos). Peak PGI2
synthetic capacity coincides with the window of receptivity,
that is, between the eight-cell and morula stages [21, 22].
Recent reports indicate that human [23]a n dm o u s e[ 24,
25] preimplantation embryos express COX isoenzymes and
synthesize eicosanoids. PGI2 is the most abundant metabo-
lite when radio-labeled arachidonic acid is incubated with
blastocyst-stage mouse embryos. Other eicosanoids, such as
HETEs and PGD2 are also produced by mouse blastocysts
[24].
6. RXR IN GAMETES AND PREIMPLANTATION
EMBRYOS
Gametes and preimplantation embryos express RXRs.
Whereas RXRγ-null mice are normal [26], RXRα-[ 27]a n d
RXRβ-null mice [28] have distinctive phenotypes. Gene
knockout studies show that spermatogenesis requires RXRβ.
Similarly, oocyte development may be modulated by RXR,
which is expressed in both granulosa-cumulus cells and
oocytes. Finally, the quality of embryo development may be
associated with RXR expression.
6.1. RXRingametes
RXRα and RXRβ are expressed in human cumulus granu-
losa cells [29] and bovine oocytes [30]. Although the initial
reports on RXRα [27]a n dR X R β [28] null mice did not in-
clude a description of female reproduction (such as follicular
development and ovulation), the localization of RXRα and β
in the ovary supports their roles in follicular maturation and
oocyte function. RXR may regulate oocyte development di-
rectly (via modulating steroidogenesis in the granulosa cells)
or indirectly (by aﬀecting oocyte gene transcription) [31]. It
islikelythatfemalemicewithtargetedRXRdeletionmaysuf-
fer subfertility.
The male sterility observed in RXRβ-null mice [28]u n -
derscores the essential role of RXR (and its functional part-
ner) in spermatogenesis. In mouse testes, retinoic acid recep-
tors (RARs) and RXR are expressed in well-deﬁned cell pop-
ulations: RARα and RXRβ in Sertoli cells, RARβ,R X R α,a n d
RXRγ in steps 7 and 8 spermatids, and RARγ in spermato-
gonia. Mouse spermatocytes, however, do not express RARs
[32]. Although RARβ,R X R α,a n dR X R γ are coexpressed in
step 7 and 8 spermatids, RARβ may not functionally cou-
ple with either RXRα or RXRγ, because RARβ-, RXRγ-, and
RARβ/RXRγ-null mice do not display reproductive defects
[32]. On the other hand, RXRβ and RARα may form het-
erodimer and control spermiation in vivo because both are
coexpressed in Sertoli cells and invalidation of either gene in
mice leads to similar phenotype [32]. RXRβ-null males are
sterile due to oligoasthenoteratozoospermia caused by failed
spermatid release (from the germinal epithelium) and ab-
normal sperm acrosomes and tails [27]. In Sertoli cells, the
function of RXRβ (coupled with RARα) may involve lipid
metabolism or transport, because they progressively accu-
mulate lipids (which are unsaturated triglycerides) in RXRβ-
null mice. In older RXRβ-null males, germ cells degenerate
completely and seminiferous tubules are ﬁlled with lipid vac-
uoles [27]. RARα homozygous mutant [33]a n dm i c ew i t h
targeted RARα ablation in Sertoli cells [34] display similar
phenotype. Both have testicular degeneration, failed spermi-
ation, epithelial vacuolation, germ cell desquamation, and
apoptosis [34]. Although there is no report concerning RXR
expression in spermatozoa, it can be inferred that human
sperm express RXR because human sperm express PPARγ
(which forms functional complex with RXR) and PPARγ lig-
and enhances their activities [35].
6.2. RXRinpreimplantationembryos
The development of preimplantation embryos was not de-
scribed in the initial reports describing RXRα-[ 27]a n d
RXRβ-[ 28] null mice. However, available information in the
literatureshowsthatpreimplantationembryosexpressRXRs.
Transcripts of RXRα,R X R β,a n dR X R γ are expressed in
zebraﬁsh embryos at 1.5hour postfertilization [36]. RXRα,
RXRβ,a n dR A L D H 2 (one of the two enzymes oxidizing
retinol to retinoic acid) are detected in all stages of preim-
plantation bovine embryos, including blastocysts which ex-
press RXRβ protein in the inner cell mass and the trophec-
toderm [30]. RXRα, β,a n dγ transcripts in preimplanta-
tion bovine embryos are likely of maternal origin because
eight-cell stage and earlier embryos have signiﬁcantly higher
RXRlevelsthanlaterstageembryos[37].Furthermore,RXRs
may be essential for optimal embryo development because
“good-quality” embryos express signiﬁcantly higher levels of
RXR transcripts than “bad-quality” embryos [37]. It can be
summarized that RXR expression in preimplantation em-
bryosdescribedaboveiscorroboratedbytheexpressionofits
partner,PPAR(discussedlater).Furthermore,RXR(partners
with PPAR or RAR) is crucial to normal embryo develop-
ment because (1) early stage embryos contain high levels of
maternal RXR mRNA, and (2) “good-quality” embryos ex-
press higher RXR mRNA levels.
7. PPAR IN GAMETES AND PREIMPLANTATION
EMBRYOS
Compared with their role in postimplantation embryo de-
velopment, the roles of PPARs in fertilization, implantation,
and embryo development are less well deﬁned. Available in-
formation does suggest that gametes and preimplantation
embryos express functional PPARs and that PPAR activation
optimizes their functions.
7.1. PPARandgametes
All three PPAR isotypes are expressed in somatic and germ
cells of the testis. In rat, PPARα and β/δ are expressed in
Leydig cells and Sertoli cells [38]. In human, PPARγ1m e s -
sage is detected in the testis [39]. In mouse, both PPARα
and γ are expressed in Sertoli cells [40], and PPARβ/δ is ex-
pressed in spermatids and spermatocytes [41]. The expres-
sion of PPARβ/δ in mouse spermatids and spermatocytes is
further supported by the expression of Ssm,an o v elP P A R β/δ4 PPAR Research
target gene, in mouse testis [42]. The functionality of PPARα
in Sertoli cells is conﬁrmed by its nuclear translocation in re-
sponse to a selective PPARα ligand, Wy-14,643 [40]. These
ﬁndings suggest that PPARs (in Sertoli cells and Leydig cells)
provide an environment for spermatogenesis and may be di-
rectly involved in germ cell maturation. PPAR may regu-
late germ cell maturation in a stage-dependent fashion. In
zebraﬁsh, PPARγ is expressed in spermatogonia but not in
spermatocytes [43].
PPAR ligand aﬀects spermatogenesis and sperm activi-
ties. Di(n-butyl) phthalate, a PPAR activator, modulates the
expression of genes related to spermatogenesis and steroido-
genesis and causes testicular atrophy in rats [44]. In contrast,
the capacitation, acrosome reaction, and motility of ejacu-
latedhumanspermareenhancedbyatreatmentwithrosigli-
tazone (a synthetic PPARγ ligand) or 15d-PGJ2 (a natural
PPARγ ligand) [35]. Since germ cells express all three PPAR
isotypes, the expression and function of two other PPAR iso-
types, PPARα and β/δ, in mature spermatozoa warrant fur-
ther investigation.
In several species including rat, all three PPAR isotypes
are detected in the ovary [2]. PPARγ, which has been stud-
ied more extensively than the other two isotypes, is detected
in the mouse, rat, pig, sheep, cow, and human ovary. PPARγ
is expressed strongly in the granulosa cells of rat [2], mouse
[41], and sheep [45], as well as in oocytes from cattle [30],
zebraﬁsh [43], Xenopus [46], and human [47]. PPARγ is de-
tected in diﬀerent classes of follicles (primary/secondary to
preovulatory follicles) and its expression increases with the
development of follicles. After the LH surge, PPARγ mRNA
expressionisdownregulated[2].ActivationofPPARγ bynat-
ural and synthetic ligands in the granulosa cells appears to
regulatethesynthesisofsteroidhormones.Thus,PPARγ may
be indirectly involved in oocyte maturation via the granu-
losa cells. Indeed, disruption of PPARγ gene in the ovary us-
ing cre/loxP technology led to female subfertility [48]. On
the other hand, PPARs may be directly involved in oocyte
maturation. Indeed, it has been reported that rosiglitazone, a
syntheticPPARγ ligand,at100μMstimulatesAMP-activated
protein kinase (AMPK) and enhances the meiotic resump-
tion of mouse oocytes [42].
7.2. PPARandpreimplantationembryos
Preimplantation bovine and mouse embryos express PPARγ
and PPARβ/δ, respectively. Beginning at two-cell stage and
throughout the preimplantation period, bovine embryos ex-
pressPPARγ.BlastocyststagebovineembryosexpressPPARγ
in the inner cell mass and the trophectoderm [30]. Mouse
embryos express PPARβ/δ detectable by immunohistochem-
istry at two-cell stage [25] or eight-cell stage [22]a n d
throughout the preimplantation period. Mouse blastocysts
also express PPARβ/δ in the inner cell mass and the trophec-
toderm [22].
Although preimplantation embryo development and im-
plantation were not speciﬁcally examined in the initial re-
port regarding PPARβ/δ-null mouse, the report provides a
hint of the impacts of PPARβ/δ deﬁciency [49]. The geno-
typicdistributionofembryosongestationday9.5showsthat
PPARβ/δ−/− embryos are underrepresented: PPARβ/δ−/−
embryos represent 16% (3/19) and 38% (3/8) of embryos
from PPARβ/δ + /− xP P A R β/δ + /− and PPARβ/δ − /− x
PPARβ/δ + /− mating, respectively. This represents a 36%
(i.e., 25% versus 16%) and a 24% (i.e., 50% versus 38%)
deviation from the expected Mendelian frequency. Loss of
PPARβ/δ − /− embryos prior to gestation day 9.5 may oc-
curatanystageincludingovulation,fertilization,preimplan-
tation period, implantation, and postimplantation period
up to gestation day 9.5. The results of our study show that
PPARβ/δ ablation adversely aﬀects preimplantation embryo
development and, consequently, implantation [22]. Com-
pared with wild-type embryos, PPARβ/δ−/− embryos show
developmental delay as early as 48hours after two-cell stage
embryos are harvested. The gap widens in the subsequent
48hours. At 96hours after the harvest of two-cell embryos,
100% of wild-type embryos have reached or passed the blas-
tocyst stage (versus 65% PPARβ/δ − /− embryos), and 85%
of wild-type embryos have undergone hatching or hatched
completely (versus 28% PPARβ/δ − /− embryos). Conse-
quently, PPARβ/δ −/− embryos implant less eﬀectively than
wild-type embryos (28% versus 44%). We also found that
PPARβ/δ−/−embryoshavedecreasedembryoniccellprolif-
eration compared with that observed in wild-type embryos.
These results suggest that PPARβ/δ activation via endoge-
nous PPARβ/δ ligand, such as PGI2 [24] and/or retinoic acid
[18], confers the “basal” momentum (including cell prolifer-
ation and possibly other functions) to preimplantation em-
bryos and propels them through various stages of develop-
ment.
Inaddition to providing a“basal”momentumofembryo
development via endogenous PPARβ/δ ligand, PPARβ/δ ac-
tivation by synthetic ligand further enhances the develop-
ment and the implantation of cultured embryos. Both L-
165041 (a synthetic PPARβ/δ ligand) and iloprost (a sta-
ble PGI2 analog) enhance complete embryo hatching in a
concentration-dependentmanner[22,50,51].Embryospre-
conditioned with L-165041 or iloprost show higher implan-
tation rates when transferred to gestational carriers [22, 52].
These results suggest that cultured embryos do not reach
theirfulldevelopmentalpotentialduetoinsuﬃcientendoge-
nous PPARβ/δ ligands or lack of exogenous PPARβ/δ lig-
ands normally provided by the oviduct. Embryos exposed to
PPARβ/δ ligand have increased embryonic cell proliferation
compared with controlled embryos [22].
8. PPAR AND REPRODUCTIVE TOXICOLOGY
PPAR activators are found in herbicides, industrial plasticiz-
ers (for a brief review see [53]), and personal care products
such as hair spray and solvent for perfumes [54]. Di(n-butyl)
phthalate, a PPARγ activator found in plasticizers and per-
sonal care products, may cause male infertility by altering
hormones involved in steroidogenesis and spermatogenesis
[44]. Other potential PPAR activators posing reproductive
toxicology concerns are pharmaceutical agents used to lower
lipids and blood glucose. Rosiglitazone (a TZD for diabetes)
may activate PPARγ ligand and enhance sperm activities in
men [35] or, depending on its concentration, may enhanceJaou-Chen Huang 5
meiosis resumption of oocytes or induce oocyte degenera-
tion in women [55]. Nonsteroidal anti-inﬂammatory drugs,
such as Motrin, which blocks PG synthesis, pose reproduc-
tive hazards through a diﬀerent mechanism. Decreased PG
(such as PGI2)p r o d u c t i o nm a ya d v e r s e l ya ﬀect embryo de-
velopment and implantation.
On the other hand, PPARs may be exploited to enhance
the success of assisted reproductive technology. The fertiliza-
tion potentials of human sperm in in vitro fertilization (IVF)
or other assisted reproductive technologies, such as artiﬁcial
insemination, may be enhanced by incubating sperm with
synthetic PPARγ ligands. The development and implanta-
tion of IVF embryos may be augmented by supplementing
culture media with PGI2 analogs, synthetic PPARβ/δ ligand,
orretinoic acid. However, potential long-termadverseeﬀects
are unknown. Large-scale clinical trials of suﬃcient power
are needed to validate the beneﬁts and to assess the harms.
9. CONCLUSION
TheliteratureonPPARsingametesandpreimplantationem-
bryos is relatively limited. Nonetheless, the consensus is that
PPAR serves to optimize gamete function and embryo devel-
opment.Furtherstudiesareneededtoshedmorelightonthe
physiologicalrolesofPPARsinreproduction.Theknowledge
gained will help us avoid potential reproductive hazards and
augment the success of assisted reproductive technologies.
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